Market Overview

Benzinga's Top Upgrades, Downgrades For January 2, 2020

Share:

Upgrades

  • Sidoti & Co. changed the rating for Comfort Systems USA Inc (NYSE: FIX) from Neutral to Buy. In the third quarter, Comfort Systems USA showed an EPS of $0.98, compared to $1.02 from the year-ago quarter. The stock has a 52-week-high of $58.21 and a 52-week-low of $36.27. Comfort Systems USA's stock last closed at $49.84 per share.
  • For Bausch Health Companies Inc (NYSE: BHC), PiperJaffray upgraded the stock from Neutral to Overweight. In the third quarter, Bausch Health Companies showed an EPS of $1.19, compared to $1.15 from the year-ago quarter. The stock has a 52-week-high of $31.97 and a 52-week-low of $18.26. Bausch Health Companies's stock last closed at $29.92 per share.
  • RBC Capital upgraded the stock for Citizens Financial Group Inc (NYSE: CFG) from Sector Perform to Outperform. Citizens Financial Group earned $0.98 in the third quarter, compared to $0.93 in the year-ago quarter. The stock has a 52-week-high of $40.92 and a 52-week-low of $29.27. Citizens Financial Group's stock last closed at $40.61 per share.
  • Compass Point upgraded the stock for Acushnet Holdings Corp (NYSE: GOLF) from Neutral to Buy. Acushnet Holdings earned $0.39 in the third quarter, compared to $0.09 in the year-ago quarter. The stock has a 52-week-high of $32.96 and a 52-week-low of $20.75. Acushnet Holdings's stock last closed at $32.54 per share.
  • For Stryker Corp (NYSE: SYK), Evercore ISI Group upgraded the stock from In-Line to Outperform. For the third quarter, Stryker had an EPS of $1.91, compared to year-ago quarter EPS of $1.69. The stock has a 52-week-high of $223.45 and a 52-week-low of $151.63. Stryker's stock last closed at $209.97 per share.
  • UBS changed the rating for Caesars Entertainment Corp (NASDAQ: CZR) from Sell to Neutral. Caesars Entertainment earned ($0.53) in the third quarter, compared to $0.14 in the year-ago quarter. The stock has a 52-week-high of $13.65 and a 52-week-low of $6.45. Caesars Entertainment's stock last closed at $13.60 per share.
  • Susquehanna upgraded the stock for Crocs Inc (NASDAQ: CROX) from Neutral to Positive. Crocs earned $0.57 in the third quarter, compared to $0.07 in the year-ago quarter. The stock has a 52-week-high of $42.27 and a 52-week-low of $17.52. Crocs's stock last closed at $41.89 per share.
  • Susquehanna upgraded the stock for Shoe Carnival Inc (NASDAQ: SCVL) from Neutral to Positive. Shoe Carnival earned $0.94 in the third quarter, compared to $0.76 in the year-ago quarter. The stock has a 52-week-high of $41.84 and a 52-week-low of $21.47. Shoe Carnival's stock last closed at $37.28 per share.
  • Citigroup changed the rating for Zimmer Biomet Holdings Inc (NYSE: ZBH) from Neutral to Buy. In the third quarter, Zimmer Biomet Holdings showed an EPS of $1.77, compared to $1.63 from the year-ago quarter. The stock has a 52-week-high of $151.67 and a 52-week-low of $98.60. Zimmer Biomet Holdings's stock last closed at $149.70 per share.
  • For The Estee Lauder Companies Inc (NYSE: EL), Citigroup upgraded the stock from Neutral to Buy. Estee Lauder Cos earned $1.67 in the first quarter, compared to $1.47 in the year-ago quarter. The stock has a 52-week-high of $208.33 and a 52-week-low of $121.47. Estee Lauder Cos's stock last closed at $206.60 per share.
  • For Wells Fargo & Co (NYSE: WFC), RBC Capital upgraded the stock from Underperform to Sector Perform. Wells Fargo earned $1.07 in the third quarter, compared to $1.16 in the year-ago quarter. The stock has a 52-week-high of $54.75 and a 52-week-low of $43.34. Wells Fargo's stock last closed at $53.77 per share.
  • For Baxter International Inc (NYSE: BAX), Citigroup upgraded the stock from Neutral to Buy. The stock has a 52-week-high of $89.93 and a 52-week-low of $64.13. Baxter International's stock last closed at $83.56 per share.
  • For Sirius XM Holdings Inc (NASDAQ: SIRI), JP Morgan upgraded the stock from Underweight to Overweight. For the third quarter, Sirius XM Holdings had an EPS of $0.05, compared to year-ago quarter EPS of $0.07. The stock has a 52-week-high of $7.20 and a 52-week-low of $5.23. Sirius XM Holdings's stock last closed at $7.15 per share.
  • For Baxter International Inc (NYSE: BAX), Morgan Stanley upgraded the stock from Equal-Weight to Overweight. The stock has a 52-week-high of $89.93 and a 52-week-low of $64.13. Baxter International's stock last closed at $83.56 per share.

 

Downgrades

  • For Weyerhaeuser Co (NYSE: WY), Bank of America downgraded the stock from Buy to Neutral. For the third quarter, Weyerhaeuser had an EPS of $0.08, compared to year-ago quarter EPS of $0.28. The stock has a 52-week-high of $30.28 and a 52-week-low of $20.91. Weyerhaeuser's stock last closed at $30.19 per share.
  • Baird downgraded the stock for Henry Schein Inc (NASDAQ: HSIC) from Outperform to Neutral. For the third quarter, Henry Schein had an EPS of $0.90, compared to year-ago quarter EPS of $1.03. The stock has a 52-week-high of $72.81 and a 52-week-low of $56.58. Henry Schein's stock last closed at $66.72 per share.
  • Bank of America changed the rating for Louisiana-Pacific Corp (NYSE: LPX) from Buy to Neutral. In the third quarter, Louisiana-Pacific showed an EPS of $0.08, compared to $0.83 from the year-ago quarter. The stock has a 52-week-high of $30.34 and a 52-week-low of $20.71. Louisiana-Pacific's stock last closed at $29.67 per share.
  • Cowen & Co. changed the rating for Akamai Technologies Inc (NASDAQ: AKAM) from Outperform to Market Perform. In the third quarter, Akamai Technologies showed an EPS of $1.10, compared to $0.94 from the year-ago quarter. The stock has a 52-week-high of $93.12 and a 52-week-low of $57.18. Akamai Technologies's stock last closed at $86.38 per share.
  • Bank of America changed the rating for CyrusOne Inc (NASDAQ: CONE) from Buy to Neutral. For the third quarter, CyrusOne had an EPS of $0.91, compared to year-ago quarter EPS of $0.79. The stock has a 52-week-high of $79.73 and a 52-week-low of $48.94. CyrusOne's stock last closed at $65.43 per share.
  • For Abbott Laboratories (NYSE: ABT), Citigroup downgraded the stock from Neutral to Sell. Abbott Laboratories earned $0.84 in the third quarter, compared to $0.75 in the year-ago quarter. The stock has a 52-week-high of $89.24 and a 52-week-low of $65.50. Abbott Laboratories's stock last closed at $86.85 per share.
  • Citigroup changed the rating for Medtronic PLC (NYSE: MDT) from Buy to Neutral. Medtronic earned $1.31 in the second quarter, compared to $1.22 in the year-ago quarter. The stock has a 52-week-high of $115.94 and a 52-week-low of $81.66. Medtronic's stock last closed at $113.37 per share.
  • For Aflac Inc (NYSE: AFL), JP Morgan downgraded the stock from Overweight to Neutral. Aflac earned $1.16 in the third quarter, compared to $1.03 in the year-ago quarter. The stock has a 52-week-high of $57.18 and a 52-week-low of $44.28. Aflac's stock last closed at $52.89 per share.
  • For Flex Ltd (NASDAQ: FLEX), JP Morgan downgraded the stock from Overweight to Neutral. For the second quarter, Flex had an EPS of $0.31, compared to year-ago quarter EPS of $0.29. The stock has a 52-week-high of $12.87 and a 52-week-low of $7.32. Flex's stock last closed at $12.62 per share.
  • Raymond James downgraded the stock for Biomarin Pharmaceutical Inc (NASDAQ: BMRN) from Market Outperform to Market Perform. In the third quarter, Biomarin Pharmaceutical showed an EPS of $0.30, compared to ($0.07) from the year-ago quarter. The stock has a 52-week-high of $100.13 and a 52-week-low of $62.88. Biomarin Pharmaceutical's stock last closed at $84.55 per share.
  • Raymond James changed the rating for Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) from Market Outperform to Market Perform. Ultragenyx Pharmaceutical earned ($1.96) in the third quarter, compared to ($1.74) in the year-ago quarter. The stock has a 52-week-high of $74.50 and a 52-week-low of $35.41. Ultragenyx Pharmaceutical's stock last closed at $42.71 per share.
  • Raymond James changed the rating for Vertex Pharmaceuticals Inc (NASDAQ: VRTX) from Market Outperform to Market Perform. For the third quarter, Vertex Pharmaceuticals had an EPS of $1.23, compared to year-ago quarter EPS of $1.09. The stock has a 52-week-high of $225.66 and a 52-week-low of $160.95. Vertex Pharmaceuticals's stock last closed at $218.95 per share.
  • Morgan Stanley downgraded the stock for Globus Medical Inc (NYSE: GMED) from Overweight to Equal-Weight. In the third quarter, Globus Medical showed an EPS of $0.43, compared to $0.39 from the year-ago quarter. The stock has a 52-week-high of $60.15 and a 52-week-low of $38.01. Globus Medical's stock last closed at $58.88 per share.
  • Morgan Stanley changed the rating for Hologic Inc (NASDAQ: HOLX) from Equal-Weight to Underweight. Hologic earned $0.65 in the fourth quarter, compared to $0.58 in the year-ago quarter. The stock has a 52-week-high of $53.74 and a 52-week-low of $37.68. Hologic's stock last closed at $52.21 per share.

 

Initiations

  • With a rating of Overweight, JP Morgan initiated coverage on GW Pharmaceuticals PLC (NASDAQ: GWPH). The price target is set at $134.00 for GW Pharmaceuticals. In the fourth quarter, GW Pharmaceuticals showed an EPS of ($0.04), compared to ($0.23) from the year-ago quarter. The stock has a 52-week-high of $196.00 and a 52-week-low of $95.00. GW Pharmaceuticals's stock last closed at $104.56 per share.
  • PiperJaffray initiated coverage on Moderna Inc (NASDAQ: MRNA) with an Overweight rating. The price target for Moderna is set at $24.00. In the third quarter, Moderna earned ($0.37). The stock has a 52-week-high of $29.79 and a 52-week-low of $11.54. Moderna's stock last closed at $19.56 per share.
  • With a rating of Buy, Goldman Sachs initiated coverage on Moderna Inc (NASDAQ: MRNA). The price target is set at $25.00 for Moderna. In the third quarter, Moderna earned ($0.37). The stock has a 52-week-high of $29.79 and a 52-week-low of $11.54. Moderna's stock last closed at $19.56 per share.
  • With a rating of Buy, Needham initiated coverage on Moderna Inc (NASDAQ: MRNA). The price target is set at $28.00 for Moderna. Moderna earned ($0.37) in the third quarter. The stock has a 52-week-high of $29.79 and a 52-week-low of $11.54. Moderna's stock last closed at $19.56 per share.
  • Oppenheimer initiated coverage on Moderna Inc (NASDAQ: MRNA) with an Outperform rating. The price target for Moderna is set at $27.00. Moderna earned ($0.37) in the third quarter. The stock has a 52-week-high of $29.79 and a 52-week-low of $11.54. Moderna's stock last closed at $19.56 per share.
  • With a rating of Overweight, JP Morgan initiated coverage on Moderna Inc (NASDAQ: MRNA). The price target is set at $22.00 for Moderna. In the third quarter, Moderna earned ($0.37). The stock has a 52-week-high of $29.79 and a 52-week-low of $11.54. Moderna's stock last closed at $19.56 per share.
  • With a rating of Buy, Bank of America initiated coverage on Moderna Inc (NASDAQ: MRNA). The price target is set at $20.00 for Moderna. Moderna earned ($0.37) in the third quarter. The stock has a 52-week-high of $29.79 and a 52-week-low of $11.54. Moderna's stock last closed at $19.56 per share.
  • Canaccord Genuity initiated coverage on Insmed Inc (NASDAQ: INSM) with a Buy rating. The price target for Insmed is set at $20.00. In the third quarter, Insmed showed an EPS of ($0.68), compared to ($1.14) from the year-ago quarter. The stock has a 52-week-high of $33.13 and a 52-week-low of $12.74. Insmed's stock last closed at $23.88 per share.
  • Canaccord Genuity initiated coverage on Paratek Pharmaceuticals Inc (NASDAQ: PRTK) with a Buy rating. The price target for Paratek Pharmaceuticals is set at $14.00. In the third quarter, Paratek Pharmaceuticals showed an EPS of ($1.00), compared to ($1.01) from the year-ago quarter. The stock has a 52-week-high of $7.39 and a 52-week-low of $2.66. Paratek Pharmaceuticals's stock last closed at $4.03 per share.
  • With a rating of Overweight, Barclays initiated coverage on Moderna Inc (NASDAQ: MRNA). The price target is set at $20.00 for Moderna. Moderna earned ($0.37) in the third quarter. The stock has a 52-week-high of $29.79 and a 52-week-low of $11.54. Moderna's stock last closed at $19.56 per share.
  • Morgan Stanley initiated coverage on Moderna Inc (NASDAQ: MRNA) with an Overweight rating. The price target for Moderna is set at $29.00. In the third quarter, Moderna earned ($0.37). The stock has a 52-week-high of $29.79 and a 52-week-low of $11.54. Moderna's stock last closed at $19.56 per share.

Posted-In: Initiations top upgradesUpgrades Downgrades Initiation Intraday Update Analyst Ratings

 

Related Articles (ABT + AFL)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
SNPSCFRAMaintains160.0
GRPNMorgan StanleyMaintains1.5
PPCCFRADowngrades30.0
HMSYCantor FitzgeraldReiterates33.0
FSLRCascendMaintains60.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com